Table 3. Progression-free survival (PFS) and overall survival (OS) with respect to the IPI, cell of origin, immunohistochemical double-positive cases and gene abnormalities of the MYC, BCL2 and BCL6 loci.
| PFS | OS | |||
|---|---|---|---|---|
| RR (95% CI) | p | RR (95% CI) | p | |
| Age, years > 60 ≤ 60 |
13 (0.8-2.1) | 0.198 | 2.2 (1.3-3.7) | 0.003 |
| Ann Arbor stage I-II III-IV |
2.4 (1.5-3.9) | <0.001 | 1.8 (1.1-2.9) | 0.019 |
| LDH Low > upper limit of normal |
2.5 (1.5-4.1) | <0.001 | 2.4 (1.4-4.2) | 0.002 |
| Extranodal sites ≤ 1 ≥ 2 |
2.1 (1.3-3.2) | 0.001 | 2.0 (1.3-3.3) | 0.003 |
| ECOG † PS ≤ 1 PS > 1 |
2.3 (1.5-3.6) | <0.001 | 2.6 (1.6-4.2) | <0.001 |
| IPI score ‡ Low (0-2) High (3-5) |
2.5 (1.6-3.9) | <0.001 | 2.7 (1.7-4.4) | <0.001 |
| Cell of origin subtype Hans Classification Non-GCB GCB |
1.9 (1.2-3.0) | 0.003 | 2.3 (1.3-3.8) | 0.001 |
| Choi Classification Non-GCB GBC |
1.8 (1.2-2.9) | 0.005 | 1.9 (1.1-3.1) | 0.010 |
| Visco-Young Classification Non-GCB GCB |
2.3 (1.4-3.7) | 0.001 | 2.3 (1.3-4.0) | 0.002 |
| MYC rMYC gMYC MYC protein expression |
1.5 (0.6-3.7) 0.5 (0.2-1.2) 0.9 (0.5-1.6) |
0.279 0.173 0.803 |
1.1 (0.4-3.2) 0.6 (0.3-1.4) 0.9 (0.5-1.8) |
0.738 0.273 0.979 |
| BCL2 rBCL2 gBCL2 BCL2 protein expression |
0.7 (0.4-1.6) 0.8 (0.3-1.8) 1.2 (0.7-2.2) |
0.477 0.648 0.410 |
0.3 (0.1-1.0) 1.1 (0.5-2.5) 1.0 (0.5-2.0) |
0.067 0.687 0.918 |
| BCL6 rBCL6 gBCL6 BCL6 protein expression |
1.0 (0.6-1.9) 0.7 (0.3-1.5) 0.6 (0.4-1.0) |
0.784 0.384 0.077 |
1.2 (0.6-2.1) 0.8 (0.4-1.6) 0.6 (0.4-1.0) |
0.514 0.565 0.048 |
| pSTAT3 protein expression | 0.9 (0.5-1.5) | 0.739 | 0.8 (0.4-1.5) | 0.484 |
| IRF4 r IRF4 g IRF4 |
- 0.9 (0.1-7.4) |
0.450 0.981 |
- 0.4 (0.1-3.4) |
0.500 0.440 |
| Double-HIT (FISH) c-MYC+/BCL2+(IHC) |
0.8 (0.2-4.6) 1.1 (0.6-2.0) |
0.874 0.625 |
0.6 (0.1-4.7) 0.9 (0.4-1.8) |
0.646 0.813 |
Abbreviations: rMYC: rearrangement of MYC; gMYC: gain of MYC locus; rBCL2: rearrangement of BCL2; gBCL2: gain of BCL2 locus; rBCL6 rearrangement of BCL6; gBCL6: gain of BCL6 locus; DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; GCB, germinal center B-cell-like; GEP, gene expression profiling; IPI, International Prognostic Index; DHL, double-hit lymphoma; IHC, immunohistochemistry. ‡ The IPI score ranges from 0 to 5, with 0 indicating the absence of prognostic factors, and 5 indicating the presence of all prognostic factors. The IPI score was stratified by the proposed RIPI score.